Mpektsis Tryfonas, Manolakis Anastasios, Kapsoritakis Andreas
Department of Gastroenterology, University Hospital of Larisa, Larisa 41100, Greece.
World J Gastroenterol. 2025 Jan 21;31(3):99983. doi: 10.3748/wjg.v31.i3.99983.
Liver cancer, and in particular hepatocellular carcinoma (HCC) is a disease of rising prevalence and incidence. To date, definitive treatment options include either surgical excision or ablation of the affected area. With increasing research on several pathways that could be involved in the progression of HCC, new elements within these pathways emerge as potential targets for novel therapies. The WNT/β-catenin pathway favors the presence of M2 tumor-associated macrophages which in turn promote tumor growth and metastasis. The inhibition of this pathway is considered a good candidate for such targeted therapeutic interventions. Interestingly, as Huang show in their recently published article, which is used in traditional Chinese medicine can exert an inhibitory effect on the β-catenin pathway and become a potential candidate for targeted pharmacotherapy against liver cancer.
肝癌，尤其是肝细胞癌（HCC），其患病率和发病率都在不断上升。迄今为止，明确的治疗选择包括手术切除或对受影响区域进行消融。随着对可能参与HCC进展的几种途径的研究不断增加，这些途径中的新元素成为新型疗法的潜在靶点。WNT/β-连环蛋白途径有利于M2肿瘤相关巨噬细胞的存在，而M2肿瘤相关巨噬细胞又反过来促进肿瘤生长和转移。抑制该途径被认为是这种靶向治疗干预的良好候选方案。有趣的是，正如黄等人在其最近发表的文章中所表明的，中药中使用的[具体药物未明确]可以对β-连环蛋白途径产生抑制作用，并成为针对肝癌的靶向药物治疗的潜在候选药物。
